ArticleInterdisciplinary cardiovascular and thoracic surgery2025
Promising early outcomes in surgical aortic valve replacement utilizing the rapid deployment approach for isolated aortic valve regurgitation.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSurgical aortic valve implantation remains the therapeutic gold standard for aortic valve regurgitation. Due to annular dilatation and lack of calcification, transcatheter aortic valve replacement is not recommended. Although rapid deployment valves allow faster implantation and excellent haemodynamics, they are currently not recommended for patients with aortic valve regurgitation. This study retrospectively analysed the use of rapid deployment prostheses in patients with pure aortic valve regurgitation.
methodsFrom 2014 to 2022, 444 rapid deployment valves were implanted. Since 2017 until 2022, 22 were used for patients with pure aortic valve regurgitation. This cohort was compared to 77 patients who had undergone rapid deployment valve implantation for pure aortic stenosis during the same time period. Both cohorts were analysed for major clinical outcomes, including pacemaker implantation, mortality, major adverse cardiovascular and cerebrovascular events (MACCE), and the need for redo surgery.
resultsIn both groups, no valve intraoperative and postoperative valve revisions were required. Transvalvular gradients were comparable between the groups (ΔPmean/max 7.1/13.3 mmHg in the aortic valve regurgitation and 7.9/14.7 mmHg in the AS cohort), and there were no paravalvular leaks. The postoperative pacemaker implantation rate was 0% for the rapid deployment group and 1.3% for the conventional valve replacement group.
conclusionsThese results suggest that rapid deployment valves can be safely applied for the treatment of patients with aortic valve regurgitation, even in the absence of calcification. This expands the surgeon's armamentarium and can be especially useful in patients requiring extensive surgery where saving aortic cross-clamp time may be especially beneficial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.